OA 中文
A Publication on the Staphylococcus Aureus Vaccine Development Done by Olymvax and Army Military Medical University

On March 18, 2020, a paper entitled “Rapid and Broad Immune Efficacy of a Recombinant Five-Antigen Vaccine against Staphylococcus Aureus Infection in Animal Models”was published by Olymvax R&D team, leading by chairman Mr. Fan Shaowen, co-authored with R&D team of Army Military Medical University, headed by Professor Zou Quanming. This article is published in the journal "vaccines" of the Multidisciplinary Digital Publishing Institute (MDPI).


Based on existing preclinical and clinical trial data and general consensus on candidate vaccines for S. aureus, the research teams analyzed and summarized the reasons for the failure of S. aureus vaccine development worldwide and came up with a "cocktail" vaccine, which is a recombinant vaccine, containing 5 conserved antigens. Through animal studies and phase I clinical trial studies, Olymvax and Army Military Medical University R&D teams optimize immunization schedule and finally get a best vaccination program for target population of high risk in hospitals.

The development of Staphylococcus aureus vaccine is a long and arduous process. As early as the company was founded, Olymvax initiated the cooperation with Army Military Medical University. At this stage , Olymvax eventually meet some positive results. Meanwhile, Olymvax is also carrying on the research on a therapeutic Staphylococcus aureus immunoglobulin, adopting a "two-pronged approach to prevention and treatment", with the final goal to contribute to human health.

Original publication is linked to: https://www.mdpi.com/2076-393X/8/1/134/htm